Immuron (ASX:IMC) entered into an exclusive distribution agreement to launch Calmino's ProlBS product in Australia and New Zealand, according to a Wednesday Australian bourse filing.
Calmino developed ProIBS for the treatment of symptoms related to irritable bowel syndrome.
The collaborative fee-free agreement includes all marketing and sales activities of ProlBS, the filing added.
Company shares were down nearly 3% in recent Wednesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。